Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-14

Safety of progestins in hormone replacement therapy: Molecular mechanism and clinical application

Objective

Objectives:
To study the molecular basis of estrogen and progestin regulation of cell proliferation in uterus- and mammary gland.
To develop cell/tissue culture and transgenic ("knock-out") animal models for studying the action of sex steroids and for testing new progestins.
To study the biological properties of new synthetic progestins for their suitability for HRT.

Brief description:
The major benefits and potential risks of long term progestin therapy are associated with their ability to regulate cell proliferation in the uterus and the mammary gland. Thus, it is important to learn what are true progestin effects in these organs as well as what are the combinatory effects of estrogens and progestins. The effects of long term progestine treatment on the uterus will be studied in women receiving progestin therapy. The effects of short- and long-term estrogen and progestin administration will be studied in more detail by using experimental animals and the molecular basis of these effects will be studied in vitro in mammary gland- and uterus-derived cell lines and explant cultures. These studies aim to unravel the mechanism of the effects of estrogen and progestins in the uterus and the mammary gland. In addition, a development of a transgenic (gene "knock out") model for testing new progestins has been started. These mice express only one of the two progesterone receptor isoforms and will serve as models to study different and sometimes opposite effects of some synthetic progestins through these two different receptor isoforms. New progestins aiming at the establishment of progestins with narrow tissue specificity will be characterised in multiple in vitro and in vivo approaches. The aim will be a development of new tissue specific progestins which can oppose estrogen induced cell proliferation in the uterus, but which do not have proliferation stimulating effects in mammary gland.

Keywords:
progestins, estrogen, hormone replacement therapy, mammary gland, endometrium, in vitro models, cell cycle, cell proliferation, apoptosis, carsinogenesis.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

Data not available

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CSC - Cost-sharing contracts

Coordinator

UNIVERSITY OF TAMPERE
EU contribution
No data
Address
4,Medisiinarinkatu 3
33014 TAMPERE
Finland

See on map

Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (4)

My booklet 0 0